Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

The conversation discusses skepticism towards unconventional hair loss remedies, emphasizing the effectiveness of proven treatments like oral DHT blockers, topical minoxidil, and finasteride. It criticizes misleading advice and highlights the importance of starting effective treatments early.

The conversation is about managing hair care routines while using minoxidil and finasteride for hair loss treatment. Users discuss application timing, washing frequency, and additional scalp care tips to maintain consistency and effectiveness.

The user experienced varying results with different hair loss treatments, including finasteride, minoxidil, RU58841, and dutasteride, with recent increased shedding after switching to a higher dose of dutasteride. They suspect the shedding is due to the dutasteride dose increase and question the effectiveness of dutasteride tablets from India.

Finasteride prices vary widely across Europe, with some users opting to buy 5mg tablets and split them to save money. Many find 1mg tablets more expensive, and some suggest importing from countries like India for cheaper options.

A 19-year-old plans to use an experimental hair loss treatment stack including micro-needling, Minoxidil, Pyrilutamide, Ketoconazole shampoo, and other unreleased compounds like PP405. Users advise against using unverified treatments and suggest sticking to proven options like Finasteride, with some recommending topical application to avoid side effects.

A 24-year-old is using daily dutasteride 0.5 mg for hair loss and considering whether to add minoxidil. Most users suggest continuing with dutasteride alone for now, as it shows promising results and adding minoxidil might cause unnecessary shedding.

The user is using oral minoxidil, finasteride, and a dermaroller for hair loss but is not seeing significant progress after three months. Suggestions include continuing treatment for at least a year, considering dutasteride, adding topical minoxidil, or possibly getting a hair transplant.

Switching from finasteride to dutasteride can improve hair regrowth with fewer side effects for some users. Concerns about shedding, lack of improvement, and the long-term safety of oral minoxidil remain.

A 20-year-old male experienced early hair thinning due to male pattern baldness and successfully thickened his hair using oral finasteride and topical minoxidil. The conversation highlights the importance of early action and overcoming fear of medication side effects.

The user is considering switching from finasteride and minoxidil to dutasteride for better hair regrowth results, as they are experiencing thinning and shedding despite current treatments. They have also tried microneedling, Clobetasol, and salicylic acid to manage scalp issues and inflammation.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

The conversation discusses using a 0.03% topical Dutasteride solution for hair loss, as it may be more effective than Finasteride with fewer systemic side effects. OP plans to apply it daily for 100 days, then reduce frequency, due to past negative cognitive effects from oral treatments.

Creatine does not cause or worsen hair loss, despite some anecdotal reports of hair thinning. The discussion emphasizes that these reports are not supported by scientific evidence.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

A user experienced issues with an order from Umbrella Labs, initially not receiving their product, PP405, and facing poor customer service, but eventually received the order after posting about it. Other users also reported similar problems with incomplete orders and lack of communication from the company.

The user experienced severe hair loss despite using Minoxidil and Finasteride and is considering switching to Dutasteride. Others recommend consulting a dermatologist, checking for health issues, and trying Dutasteride and oral Minoxidil.

Early hair loss causes emotional distress, and common coping strategies like fitness and fashion are inadequate. Treatments like finasteride, minoxidil, dutasteride, hair systems, and scalp micropigmentation were tried but were unsatisfactory.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The user experienced initial improvement in hair loss with oral finasteride and minoxidil but later faced increased shedding and thinning. They switched to dutasteride, hoping for better results, while continuing topical minoxidil.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A 28-year-old is experiencing hair loss despite using treatments like oral minoxidil, finasteride, and high-dose dutasteride (2.5 mg). They suspect lichen planus might be contributing to the issue and plan to continue treatment while monitoring progress.

The user shared progress pictures showing significant hair regrowth from using finasteride, RU58841, and liquid minoxidil, emphasizing the importance of consistency. They noted that RU58841, a research chemical not FDA-approved, was effective when applied topically but warned of potential heart-related side effects.

A 23-year-old male shares positive results after 6 months of using oral finasteride and minoxidil for hair loss, noting initial shedding but no side effects. He plans to continue the treatment long-term, emphasizing the importance of early intervention.

The user is using 5 mg of oral minoxidil, 1.25 mg of finasteride, and a dermaroller for hair loss, and plans to reduce the minoxidil dosage after a year. They have not experienced side effects like facial bloating and are considering the safety of long-term use.

The user has been using dutasteride and finasteride but still experiences hair loss and high DHT levels. They plan to try topical finasteride and RU58841 while continuing dutasteride to see if topicals are more effective.